Drugs / rBV A/B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00098098 | Aug 2004 → Aug 2005 | salivary substance, Clostridium botulinum type | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rBV A/B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00098098 ↗ |
| Known as | recombinant Botulinum Vaccine | “two-dose regimen (Day 0 and Day 28) of recombinant Botulinum Vaccine (rBV) A/B in healthy volunteers” NCT00098098 ↗ |
| Modality | Vaccine | “Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults” NCT00098098 ↗ |
| Route | Intramuscular | “given as a 0.5 mL intramuscular (i.m.) injection on Day 0 and Day 28” NCT00098098 ↗ |